Citations

Clear

5 citation(s) found for "Schwarz, Jacob".

Real-World Phenobarbital Use, Treatment Escalation, and Clinical Outcomes in Critically Ill Patients With Alcohol Withdrawal Syndrome: A Multicenter Propensity-Matched Cohort Study
Rizwan, Zeeshan, Dierkhising, Ross, Stark, J , Schwarz, Jacob , Toufar, Sara, Marquez, Alberto , Rovati, Lucrezia , Gajic, Ognjen, Rizwan, Zeeshan M , Heybati, Kiyan , Stark, Jacqueline L, Gajic, Ognjen

Mayo Clinic

Critical Care Explorations | August 18, 2026 | Volume: 8 | Issue: 8 | Pages: e1466

10.1097/cce.0000000000001466 | PMID 42611632 Get It

IMPORTANCE: Phenobarbital use in ICU alcohol withdrawal syndrome (AWS) may reflect severe or refractory withdrawal and treatment escalation, making multicenter data important to understand its use within ICU practice and its relationship with clinical outcomes. OBJECTIVES: To evaluate phenobarbital use in real-world ICU AWS as a marker of severe or refractory withdrawal and treatment escalation. We also examined its association with time-to-discharge and safety outcomes compared with nonphenobarbital regimens. DESIGN, SETTING, AND PARTICIPANTS: Multicenter retrospective cohort study using multiple imputation and propensity score matching. Adults with AWS, defined as Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) score greater than or equal to 10, were included if they received a phenobarbital-based or nonphenobarbital-based regimen in ICUs across a large academic health system from June 30, 2017, to July 1, 2024. Postoperative ICU admissions were excluded. MAIN OUTCOMES AND MEASURES: Primary outcomes were time to ICU and hospital discharge alive from treatment initiation. Safety outcomes were hypotension, new intubation, and aspiration within 48 hours. RESULTS: Of 1216 patients, 345 (28.4%) received phenobarbital. Before matching, phenobarbital-treated patients had higher CIWA-Ar, Acute Physiology and Chronic Health Evaluation III, and pre-ICU benzodiazepine exposure, consistent with more severe or refractory withdrawal. In adjusted time-to-discharge models, phenobarbital use was not significantly associated with time to hospital discharge alive (discharge rate ratio [DRR], 0.91; 95% CI, 0.74–1.12; p = 0.370) or ICU discharge alive (DRR, 0.77; 95% CI, 0.59–1.01; p = 0.057). Hypotension and intubation were similar, and aspiration was less frequent with phenobarbital. CONCLUSIONS: In a contemporary ICU cohort, phenobarbital use reflected treatment escalation in patients with more severe or refractory AWS. After adjustment, time to ICU and hospital discharge alive did not differ significantly, hypotension and intubation were similar, and aspiration was less frequent with phenobarbital. Future studies should define optimal timing, dosing, and patient selection.
Use of Prucalopride in Severe Ileus in a Critically Ill Patient With Acute Alcoholic Hepatitis and Hepatic Encephalopathy
Swanson, Adam , Schwarz, Jacob S., Bektas, Aeryana N., Liu, Jia

Mayo Clinic

ACG Case Reports Journal | July 23, 2026 | Volume: 13 | Issue: 7 | Pages: No page available

10.14309/crj.0000000000002248 | PMID 42495164 Get It

ABSTRACT Ileus is a common gastrointestinal complication in critically ill patients, posing a unique management challenge due to its multifactorial etiology and impact on clinical stability. Standard therapeutic approaches often fail in the setting of metabolic derangement and hemodynamic instability. Prucalopride, a selective 5-HT 4 receptor agonist, has demonstrated efficacy in promoting colonic motility; however, its use in severe small bowel and colonic ileus or decompensated liver disease populations remains limited. We report the case of a 28-year-old man with decompensated alcoholic hepatitis who developed severe small bowel and colonic ileus refractory to standard management. Concerns for worsening illness prompted a trial of prucalopride, which was temporally associated with rapid resolution of the ileus and remarkable improvement in radiographic imaging and clinical phenotype. Prucalopride may be a potential therapeutic option for severe small bowel and colonic ileus in critically ill patients. Further studies are warranted to delineate its safety and efficacy.
975: LEVOFLOXACIN DRUG MONITORING IN CONTINUOUS VENOVENOUS HEMODIAFILTRATION FOR LEGIONELLA PNEUMONIA
Whitenack, Kaylee, Robinson, John A. , Schwarz, Jacob B. , Robinson, John, Ilges, Dan , Schwarz, Jacob

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001102564.45586.c3 Get It

1160: EOSINOPHILIC PNEUMONIA ASSOCIATED WITH LION’S MANE SUPPLEMENTATION
Robinson, John A. , Schwarz, Jacob B. , Rusk, A.M., Robinson, John, Schwarz, Jacob

Mayo Clinic

Critical Care Medicine | December 14, 2023 | Volume: 52 | Issue: 1 | Pages: S552-S552

10.1097/01.ccm.0001002804.08464.49 Get It

941: FOSPHENYTOIN TO POTENTIALLY INDUCE CLEARANCE OF TACROLIMUS LEVEL SECONDARY TO NIRMATRELVIR/RITONAVIR
Schwarz, Jacob B. , Robinson, John A. , Rusk, A.W., Heilman, Raymond L. , Cartin‐Ceba, Rodrigo , Schwarz, Jacob, Robinson, John

Mayo Clinic

Critical Care Medicine | December 14, 2023 | Volume: 52 | Issue: 1 | Pages: S442-S442

10.1097/01.ccm.0001001928.87383.08 Get It